FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162978412> ?p ?o ?g. }

• W2162978412 endingPage "38" @default.
• W2162978412 startingPage "37" @default.
• W2162978412 abstract "Glutamate excitotoxicity might contribute to the pathophysiology of amyotrophic lateral sclerosis. In animal models, decreased excitatory aminoacid transporter 2 (EAAT2) overexpression delays disease onset and prolongs survival, and ceftriaxone increases EAAT2 activity. We aimed to assess the safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis in a combined phase 1, 2, and 3 clinical trial.This three-stage randomised, double-blind, placebo-controlled study was done at 59 clinical sites in the USA and Canada between Sept 4, 2006, and July 30, 2012. Eligible adult patients had amyotrophic lateral sclerosis, a vital capacity of more than 60% of that predicted for age and height, and symptom duration of less than 3 years. In stages 1 (pharmacokinetics) and 2 (safety), participants were randomly allocated (2:1) to ceftriaxone (2 g or 4 g per day) or placebo. In stage 3 (efficacy), participants assigned to ceftriaxone in stage 2 received 4 g ceftriaxone, participants assigned to placebo in stage 2 received placebo, and new participants were randomly assigned (2:1) to 4 g ceftriaxone or placebo. Participants, family members, and site staff were masked to treatment assignment. Randomisation was done by a computerised randomisation sequence with permuted blocks of 3. Participants received 2 g ceftriaxone or placebo twice daily through a central venous catheter administered at home by a trained caregiver. To minimise biliary side-effects, participants assigned to ceftriaxone also received 300 mg ursodeoxycholic acid twice daily and those assigned to placebo received matched placebo capsules. The coprimary efficacy outcomes were survival and functional decline, measured as the slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) scores. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00349622.Stage 3 included 66 participants from stages 1 and 2 and 448 new participants. In total, 340 participants were randomly allocated to ceftriaxone and 173 to placebo. During stages 1 and 2, mean ALSFRS-R declined more slowly in participants who received 4 g ceftriaxone than in those on placebo (difference 0·51 units per month, 95% CI 0·02 to 1·00; p=0·0416), but in stage 3 functional decline between the treatment groups did not differ (0·09, −0·06 to 0·24; p=0·2370). No significant differences in survival between the groups were recorded in stage 3 (HR 0·90, 95% CI 0·71 to 1·15; p=0·4146). Gastrointestinal adverse events and hepatobiliary adverse events were more common in the ceftriaxone group than in the placebo group (gastrointestinal, 245 of 340 [72%] ceftriaxone vs 97 of 173 [56%] placebo, p=0·0004; hepatobiliary, 211 [62%] vs 19 [11%], p<0·0001). Significantly more participants who received ceftriaxone had serious hepatobiliary serious adverse events (41 participants [12%]) than did those who received placebo (0 participants).Despite promising stage 2 data, stage 3 of this trial of ceftriaxone in amyotrophic lateral sclerosis did not show clinical efficacy. The adaptive design allowed for seamless transition from one phase to another, and central venous catheter use in the home setting was shown to be feasible.National Institute of Neurological Disorders and Stroke." @default.
• W2162978412 created "2016-06-24" @default.
• W2162978412 creator A5027284548 @default.
• W2162978412 creator A5072825494 @default.
• W2162978412 creator A5089046074 @default.
• W2162978412 date "2002-01-01" @default.
• W2162978412 modified "2023-10-18" @default.
• W2162978412 title "Muerte súbita de causa desconocida tras la toma de un preparado antigripal de venta libre" @default.
• W2162978412 cites W2005005967 @default.
• W2162978412 cites W2055988190 @default.
• W2162978412 cites W2067978628 @default.
• W2162978412 cites W2075733849 @default.
• W2162978412 cites W2095795992 @default.
• W2162978412 cites W2410676106 @default.
• W2162978412 doi "https://doi.org/10.1016/s0025-7753(02)73306-x" @default.
• W2162978412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12062008" @default.
• W2162978412 hasPublicationYear "2002" @default.
• W2162978412 type Work @default.
• W2162978412 sameAs 2162978412 @default.
• W2162978412 citedByCount "0" @default.
• W2162978412 crossrefType "journal-article" @default.
• W2162978412 hasAuthorship W2162978412A5027284548 @default.
• W2162978412 hasAuthorship W2162978412A5072825494 @default.
• W2162978412 hasAuthorship W2162978412A5089046074 @default.
• W2162978412 hasConcept C126322002 @default.
• W2162978412 hasConcept C142724271 @default.
• W2162978412 hasConcept C204787440 @default.
• W2162978412 hasConcept C27081682 @default.
• W2162978412 hasConcept C2776520383 @default.
• W2162978412 hasConcept C2779134260 @default.
• W2162978412 hasConcept C2780596555 @default.
• W2162978412 hasConcept C501593827 @default.
• W2162978412 hasConcept C71924100 @default.
• W2162978412 hasConcept C86803240 @default.
• W2162978412 hasConcept C89423630 @default.
• W2162978412 hasConceptScore W2162978412C126322002 @default.
• W2162978412 hasConceptScore W2162978412C142724271 @default.
• W2162978412 hasConceptScore W2162978412C204787440 @default.
• W2162978412 hasConceptScore W2162978412C27081682 @default.
• W2162978412 hasConceptScore W2162978412C2776520383 @default.
• W2162978412 hasConceptScore W2162978412C2779134260 @default.
• W2162978412 hasConceptScore W2162978412C2780596555 @default.
• W2162978412 hasConceptScore W2162978412C501593827 @default.
• W2162978412 hasConceptScore W2162978412C71924100 @default.
• W2162978412 hasConceptScore W2162978412C86803240 @default.
• W2162978412 hasConceptScore W2162978412C89423630 @default.
• W2162978412 hasIssue "1" @default.
• W2162978412 hasLocation W21629784121 @default.
• W2162978412 hasLocation W21629784122 @default.
• W2162978412 hasOpenAccess W2162978412 @default.
• W2162978412 hasPrimaryLocation W21629784121 @default.
• W2162978412 hasRelatedWork W2028651392 @default.
• W2162978412 hasRelatedWork W2139560421 @default.
• W2162978412 hasRelatedWork W2390227121 @default.
• W2162978412 hasRelatedWork W2396093483 @default.
• W2162978412 hasRelatedWork W267745054 @default.
• W2162978412 hasRelatedWork W3003199299 @default.
• W2162978412 hasRelatedWork W4231060511 @default.
• W2162978412 hasRelatedWork W4232324580 @default.
• W2162978412 hasRelatedWork W4233016836 @default.
• W2162978412 hasRelatedWork W2031566728 @default.
• W2162978412 hasVolume "119" @default.
• W2162978412 isParatext "false" @default.
• W2162978412 isRetracted "false" @default.
• W2162978412 magId "2162978412" @default.
• W2162978412 workType "article" @default.